
CHICAGO — In this Healio Video Perspective from the AAO meeting, Burton J. Kushner, MD, discusses the positive impact the CureSight platform may have on pediatric amblyopia.
“The CureSight program is the only dichoptic treatment that has undergone a prospective randomized clinical trial comparing it to the standard of care, patching, and the results were that it was noninferior,” Kushner said.